ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% - Fierce Pharma
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% Fierce Pharma A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China CNBC Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer statnews.com Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Yahoo Finance Lung Cancer Patients on Drug From China’s Akeso Lived Longer Bloomberg
YesNo はこのニュースをサイト内のライブシグナルとして保存し、検索ユーザーが予測市場や孵化中テーマとの関係を理解しやすくします。
今後、明確な期限、公式ソース、検証可能な結果が揃えば、この公共イベントは取引可能な Yes/No 質問になり得ます。
このニュースは検証可能なイベント要素を持ち、Yes/No 予測問題につながる可能性があります。